Study results showed that combining Videssa® Breast with imaging improves breast cancer detection and significantly reduces the total number of biopsies in patients with abnormal imaging findings. Results below are from two prospective clinical trials, which examined women ages 25 to 75 with a BI-RADS 3, 4 or 5 assessment.
Videssa Breast would have reduced the total number of biopsies by 45 percent.
Provista has conducted two prospectively collected, randomized, blinded, multi-center clinical trials, which enrolled patients from 15 sites across the US to evaluate the ability of Videssa Breast to detect the presence or absence of breast cancer in patients with abnormal imaging findings.
© 2017 Provista Diagnostics, Inc. All rights reserved. Contact Us | Terms of Use | Privacy Policy | Website Design by SmartBug Media
Videssa Breast is currently not available for ordering by prescribing Healthcare Providers in the State of the New York.